Open | - |
Close | - |
Volume / Avg. | 0 / 1.658M |
Day Range | - - - |
52 Wk Range | 19.830 - 94.750 |
Market Cap | $6.784B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 34 |
Short Interest | 9.89% |
Days to Cover | 6.83 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Apellis Pharmaceuticals (NASDAQ: APLS) through any online brokerage.
Other companies in Apellis Pharmaceuticals’s space includes: Immunovant (NASDAQ:IMVT), Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT) and Ionis Pharmaceuticals (NASDAQ:IONS).
The latest price target for Apellis Pharmaceuticals (NASDAQ: APLS) was reported by JP Morgan on Wednesday, March 6, 2024. The analyst firm set a price target for 79.00 expecting APLS to rise to within 12 months (a possible 40.42% upside). 68 analyst firms have reported ratings in the last year.
The stock price for Apellis Pharmaceuticals (NASDAQ: APLS) is $56.26 last updated March 18, 2024 at 4:20 PM EDT.
There are no upcoming dividends for Apellis Pharmaceuticals.
Apellis Pharmaceuticals’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for Apellis Pharmaceuticals.
Apellis Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.